Brokerages Expect Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Will Announce Quarterly Sales of $230,000.00

Equities research analysts predict that Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) will report sales of $230,000.00 for the current quarter, Zacks reports. Three analysts have provided estimates for Bellicum Pharmaceuticals’ earnings, with the highest sales estimate coming in at $300,000.00 and the lowest estimate coming in at $100,000.00. Bellicum Pharmaceuticals reported sales of $290,000.00 during the same quarter last year, which indicates a negative year-over-year growth rate of 20.7%. The firm is expected to announce its next quarterly earnings report on Tuesday, November 5th.

On average, analysts expect that Bellicum Pharmaceuticals will report full year sales of $3.70 million for the current fiscal year, with estimates ranging from $1.20 million to $9.00 million. For the next year, analysts expect that the company will report sales of $14.88 million, with estimates ranging from $1.30 million to $38.00 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.04). Bellicum Pharmaceuticals had a negative return on equity of 169.33% and a negative net margin of 4,081.44%. The company had revenue of $1.39 million during the quarter, compared to the consensus estimate of $0.23 million.



A number of research analysts have recently issued reports on BLCM shares. ValuEngine raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Thursday, August 8th.

Shares of Bellicum Pharmaceuticals stock traded up $0.02 on Friday, hitting $0.97. The stock had a trading volume of 826,645 shares, compared to its average volume of 524,106. The stock has a 50 day moving average of $1.44 and a 200 day moving average of $2.55. Bellicum Pharmaceuticals has a twelve month low of $0.78 and a twelve month high of $7.26. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.67 and a current ratio of 2.67. The firm has a market capitalization of $43.83 million, a P/E ratio of -0.40 and a beta of 1.48.

A number of hedge funds and other institutional investors have recently modified their holdings of BLCM. JPMorgan Chase & Co. boosted its position in shares of Bellicum Pharmaceuticals by 4.9% during the 1st quarter. JPMorgan Chase & Co. now owns 4,190,020 shares of the biopharmaceutical company’s stock valued at $14,120,000 after acquiring an additional 194,226 shares during the last quarter. Nikko Asset Management Americas Inc. boosted its position in shares of Bellicum Pharmaceuticals by 98.5% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 2,105,649 shares of the biopharmaceutical company’s stock valued at $3,580,000 after acquiring an additional 1,044,811 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Bellicum Pharmaceuticals by 98.5% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,105,649 shares of the biopharmaceutical company’s stock valued at $3,580,000 after acquiring an additional 1,044,811 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Bellicum Pharmaceuticals by 58.7% during the 2nd quarter. Renaissance Technologies LLC now owns 1,564,959 shares of the biopharmaceutical company’s stock valued at $2,660,000 after acquiring an additional 579,000 shares during the last quarter. Finally, ARK Investment Management LLC boosted its position in shares of Bellicum Pharmaceuticals by 33.5% during the 1st quarter. ARK Investment Management LLC now owns 1,379,629 shares of the biopharmaceutical company’s stock valued at $4,649,000 after acquiring an additional 346,138 shares during the last quarter. Institutional investors and hedge funds own 53.13% of the company’s stock.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.

Further Reading: How to read a candlestick chart

Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.